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August 9, 2002 
Diabetic cardiomyopathy (DCM) is a common complication leading to 
accelerated cardiovascular failure in diabetic patients. Even though the exact 
mechanism(s) behind this disease still remain unclear, research from several laboratories 
including our own suggests that reactive oxygen species (ROS) play a very important role 
in the development of DCM. 
 In our lab, we have developed and characterized a diabetic transgenic mice line, 
designated OVE26, which clearly develops diabetic cardiomyopathy. Comparison of 
protein expression patterns in the hearts of 120-day-old control and diabetic mice reveals 
22 proteins that are differentially expressed in OVE26 mice hearts, most of which are 
involved in energy metabolism. Surprisingly, 10 of 20 proteins that are identified by mass 
spectrometry are located in mitochondria, suggesting mitochondria as a critical target for 
ROS damage. The finding of the up-regulation of all 10 proteins also corresponds well 
with the concept that moderate oxidative stress can stimulate mitochondrial biosynthesis 
to compensate for the impaired cell functions. Study on mitochondrial morphology also 
shows abnormal cardiac structure and damage, further pointing to mitochondria as one of 
the major sites of ROS attack in diabetic cardiomyopathy.  
 v
In an effort to prevent the mitochondrial damage we saw in diabetic hearts, we 
have developed transgenic lines that overexpress the main mitochondrial antioxidant 
protein, MnSOD specifically in cardiomyocytes. Preliminary data from the transgenic 
mice that overexpress MnSOD in diabetic heart showed that this antioxidant enzyme was 
effective in protecting the morphology of the diabetic heart.  
Our proteomic and morphologic analyses indicate that mitochondria are an 
important target of diabetic cardiomyopathy.  Protection by overexpression of 
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Diabetes mellitus is now one of the main threats to human health in the 21st 
century (1). Up to the year 2000, 14.2 million people in United States had been diagnosed 
with diabetes, and 151 million people worldwide. And these numbers are set to rise to 
17.5 and 220 million by 2010 (1;2). Prevention of diabetes and control of its 
complications are one of the greatest tasks for health scientist in the next decade.  
One of the leading causes of mortality in diabetics is heart failure (3). The 
Framingham Heart Study showed that the risk of heart failure was increased two fold 
among diabetic men and five fold among diabetic women (4). Heightened risks for heart 
failure are even more pronounced in African-Americans and certain Native Americans 
(3). 
Nearly every physician is familiar with the concept that diabetic patients have 
increased cardiovascular morbidity (5). Prior to 1972, it had been attributed to only 
vascular diseases such as hypertension and coronary arteriosclerosis. In 1972, Rubler et al. 
first suggested a specific cardiomyopathy that exists independently of coronary artery 
disease and other known cardiac risk factors (6;7). The term “diabetic cardiomyopathy” 
was therefore proposed. This work had been subsequently followed by numerous studies
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reporting similar findings (8;9), providing strong support for the existence of a specific 
diabetic cardiomyopathy with origins in diabetic cardiac muscles. 
Diabetic cardiomyopathy is manifested by early diastolic dysfunction, i.e. reduced 
left ventricular end diastolic (LVED) volume and filling rate, followed later in the disease 
by abnormalities in systolic function (3). Biopsies of the diabetic heart also revealed 
histopathological abnormalities including interstitial fibrosis, myocyte hypertrophy and 
mitochondrial abnormalities (9;10). Patients with diabetic cardiomyopathy have a much 
worse prognosis following myocardial infarction than non-diabetics even when the 
infarct size is smaller (11). When diabetic cardiomyopathy presents with other 
cardiovascular diseases such as hypertension, they exacerbate one another, adding 
significantly to their overall morbidity and mortality (12). 
Despite the obvious importance of diabetic cardiomyopathy, the underlying 
mechanisms of this complication at the cellular and molecular level are still not well 
characterized. Several mechanisms have been postulated, including free radical 
production, altered lipid content of membranes, as well as the abnormal carbohydrate 
metabolism and excessive fatty acid oxidation (3). Research from several laboratories 
including our own suggests that reactive oxygen species (ROS) play a very important role 
in the development of diabetic cardiomyopathy (13;14). But only limited data are 
available now and the pathogenesis of this disease is still unclear. In addition, little 
emphasis has been put on developing novel approaches to prevention and treatment of 
diabetic cardiomyopathy. We are expecting to make progress in characterizing the role of 
mitochondrial ROS and mitochondrial damage in this disease through this study, and also 
to shed some light on the potential application of antioxidant therapy.  
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In order to study diabetic cardiomyopathy, our laboratory has developed and 
characterized a diabetic transgenic mice line, designated OVE26 (15-18). These 
transgenic mice develop very early onset of diabetes due to the overexpression of the 
calcium binding protein calmodulin in pancreatic beta cells that induces pancreatic beta 
cell death and dysfunction. The exact mechanism of why elevated calmodulin was 
remarkably deleterious to β cells is still poorly understood, but it has been suggested that 
abnormal calcium homeostasis is harmful for both function and viability of β cells (16).  
The OVE26 transgenic mice provide us an excellent model to study diabetic 
complications. Transgenic mice demonstrate elevated blood glucose levels within the 
first days of life and have blood glucose values over 450 mg/dl by 30 to 55 days of age. 
By the time when they are 120 days old, the typical blood glucose values are over 600 
mg/dl. Surprisingly, they can survive at least a year without exogenous insulin therapy 
despite such high blood glucose levels. The specificity of the transgene and insulin 
promoter assures that calmodulin only induces the degeneration of pancreatic β cells. 
Since the diabetes is induced genetically, they require no administration of any beta cell 
toxin that might induce variability and nonspecific toxicity. Successive generations have 
continued to express their characteristic of very early onset of diabetes for more than 10 
years now. They are readily maintained because they are fertile up to 4 months of age. 
The transgenic diabetic mice can be easily recognized by the development of obvious 
cataracts resulting from the co-injection and co-integration of the cataract-inducing GR19 
gene (16;19). In summary, this OVE26 mice line is a very attractive animal model for 
study of diabetic complications because of its early onset, long life span, severe 
consistent diabetes and simple breeding and maintenance. 
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Previous studies in our laboratory have shown that OVE26 diabetic mice clearly 
exhibit cardiomyopathy characterized by significantly altered mRNA expression, severe 
morphological abnormalities, and reduced contractility under ischemic conditions (20). 
To better understand this disease on the molecular level, we decided to study changes in 
protein expression in an effort to reveal the mechanism of these deficits and some targets 
of ROS damage. 
Proteomic analysis is chosen for this purpose because of the many advantages it 
offers over other methods for analysis of protein expression.  Unlike Western blots which 
can examine the expression of only one protein at a time and which is limited by the 
availability of antibodies, proteomic analysis can examine the abundance of hundreds to 
thousands of proteins on one gel (21). What’s more, proteomic analysis is able to detect 
some post-translational modifications. For example, it is possible to observe the different 
phosphorylation states of one protein by the presence of a series of protein spots with 
similar MW since the addition or the subtraction of phosphate groups will make 
detectable change on pI but not on molecular weight (22).  
In the following study, we applied proteomic analysis to 4-month old FVB and 
OVE26 hearts to study the change of protein expressions in diabetic cardiomyopathy. 
Proteomic results combined with the observation from cardiac morphology strongly 












  Animals: We have previously described the development of OVE26 diabetic mice 
(Epstein, Overbeek, and Means 1989). Transgenic mice were recognized by the presence 
of small eyes caused by co-integration of the GR19 gene (Epstein, Overbeek, and Means 
1989). All transgenic and non-transgenic mice were maintained on the inbred FVB 
background. 
Whole heart protein extraction: Fresh heart taken from 4-month-old control and 
diabetic mice were immediately rinsed in pre-chilled PBS to wash out the blood. The 
heart was then frozen in liquid nitrogen and later transferred to –80˚C freezer for storage. 
On the day before running the 2-D gel, the heart was powdered, weighed, and 
homogenized on ice in 600ml sample buffer/100mg heart tissue. The sample buffer 
contained 7 M urea, 1.9 M thiourea, 4% CHAPS, 58 mM DTT and 4.45% pH 3-10 
carrier ampholytes. The mixture was shaken in cold room for one hour and centrifuged at 
16,000g for 10 minutes at 4 degree. The supernatant containing the soluble proteins was 
removed and aliquoted to microtubes for further use. Protein concentration was 
determined using Bio-Rad protein assay based on Bradford’s method (Bradford 1976). 
2D-PAGE: Immobilized pH gradient (IPG) strips, nonlinear pH 3-10 (Amersham 
Pharmacia Biotech Inc.) were used for the first dimension. 100 ug of protein were
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rehydrated overnight with the IPG strips in rehydration buffer containing 8 M urea, 2% 
CHAPS, 0.01 M DTT, 2% ampholytes and bromophenol blue. On the next morning, the 
sample was set up for isoelectric focusing (IEF) with maximal 5000 V and 80 uA for 24 
hours at 4˚C. Then the sample was equilibrated with buffer containing 6 M urea, 130 mM 
DTT, 30% glycerol, 112 mM Tris base, 4% SDS, 0.002% bromophenol blue and acetic 
acid twice for 20 minutes, then with buffer containing 6 M urea, 135 mM iodoacetamide, 
30% glycerol, 112 mM Tris base, 4% SDS, 0.002% bromophenol blue and acetic acid 
once for 10 minutes. For second dimension, the strips were loaded onto pre-cast 10% 
homogeneous, 20 x 20 cm slab gels (Genomic Solutions Inc.). Upper running buffer 
contained 0.2 M Tris base, 0.2 M tricine and 0.4% SDS. Lower running buffer contained 
0.625 M Tri/acetate. The system was run with maximal 500 V and 20,000 mW for 4 to 
4.5 hours at 4˚C. 
SYPRO Ruby staining: The gel was fixed in 10% methanol and 7% acetic acid for 
30 minutes. The fixation solution was removed and 500 ml of SYPRO Rudy stain (Bio-
Rad Laboratory, Hercules, CA) was added to each gel and incubated at room temperature 
for 18 hours. 
Visualization: The gel images after staining were taken by a high-resolution 12-
bit camera with UV light box system (Genomic Solutions Inc.) 1 and 3 seconds exposure 
time were used to scan the gels. The images were converted to TIFF files before the 
image analysis. 
Image analysis: The protein expression patterns in control and diabetic heart were 
compared using Investigator HT analyzer software (Genomic Solutions Inc.). First a 
virtual reference gel was created by combining all of the detectable spots into one image. 
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This image was then used to determine the existence and differential expression of 
proteins in each group. Background of the gel was subtracted using “Average on the 
boundary” and the spot intensity was normalized by using “total volume ratio x total spot 
area” to minimize the intensity variability among the gels. A t-test was used to compare 
the protein intensities in control and diabetic hearts, and p≤0.05 was considered 
significant. 
Protein spot picking and in-gel tryptic digestion: The protein spots were excised 
with a clean scalpel into 1 mm cube and transferred to clean 1.5 ml microtubes. The gel 
pieces were washed and sequentially dehydrated and rehydrated by the methods used 
described by Thongboonkerd, et al. (Thongboonkerd et al 2002). Then the gel tubes were 
chopped into smaller pieces and incubated with 20 ng/ul modified trypsin (Promega, 
Madison, WI) in 50 mM ammonium bicarbonate at 37˚C overnight in shaking incubator. 
MALDI-TOF mass spectrometry: The samples were desalted and spotted onto the 
96-well MALDI target plate by the method described by Thongboonkerd, et al. 
(Thongboonkerd, Luengpailin, Cao, Pierce, Cai, Klein, and Doyle 2002). Mass spectral 
data were obtained using a Micromass Tof-Spec 2E instrument with a 337 mM N2 laser.  
Data analysis: Protein identification from tryptic fragment sizes was performed by 
peptide mass fingerprinting using the MASCOT search engine 
(http://www.matrixscience.com). NCBInr and Swiss (ExPASY) protein databases were 
used for this purpose and MOWSE scores greater than 58 were considered statistically 
significant (p≤ 0.05). 
Heart morphology: Cardiac ultrastructure was examined by transmission electron 
microscopy (TEM) in hearts of control and transgenic mice at the age of 4-5 month. 
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Hearts from anesthetized animals were first perfused with an approximately 30 ml of 
wash-out solution containing procaine hydrochloride to prevent vasoconstriction and a 
relatively weak solution of paraformaldehyde to pre-fix the heart, followed by the full-
strength Karnovsky’s fixative 100 ml for TEM observation. The heart was then removed 
and weighed. Left ventricular wall and interventricular septum were collected for 
conventional TEM studies. Fixed tissue was sent to Dr. Carlson at the University of 
North Dakota for preparation of EM micrographs. To further quantify the morphological 
changes in different groups of hearts, EM micrographs from the hearts of FVB, OVE26, 
OVE26-MnSOD and MnSOD mice were scored by 2-3 blinded observers for overall 
morphology, regularity and continuity of myofibrils, as well as mitochondrial structure 
and distribution. Heart weights from different groups were also compared as another 
parameter for normal heart features. 
 Construction of MnSOD transgene: The construction of MnSOD transgene, 
designated MySOD is shown in Figure 4. All the enzymes used in this process were 
ordered from New England BioLabs, Beverly, MA. The alpha myosin heavy chain 
promoter was obtained from another transgene MyADH (Liang et al 1999). In our 
laboratory, we have produced over 50 transgenic lines using this promoter, and all the 
transgenes have been very active and cardiac specific. MyADH was digested by 
restriction enzymes Sal I and Hind III to remove the ADH fragment. The remaining 9 Kb 
fragment contained the α myosin heavy chain promoter, vector for transformation and the 
polyadenylation region of the rat insulin II gene. The 830 bp MnSOD fragment 
containing complete coding sequences for human manganese SOD was removed from 
transgene InSOD by EcoRI digestion, followed by gel separation and purification. The 9 
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Kb fragment from MyADH and the MnSOD fragment were then blunt-ended and ligated 
by T4 DNA ligase to accomplish the construction. The resulting DNA solution was then 
incubated with Hind III to digest and eliminate the self-ligated product of MyADH 
fragment. This solution was then used to transform XL1-Blue competent cells for 
amplification. Correct construction and orientation was verified by sequencing the 
regions across the ligation. Finally, the transgene was microinjected into mouse embryo 
to produce MnSOD transgenic mice. 
SOD enzyme activity assay: SOD activity was determined by measuring the 
inhibition of pyrogallol autoxidation (Marklund and Marklund 1974). Heart samples were 
homogenized in 1ml/25mg tissue in sample assay buffer containing 50 mM Tri-cacodylic 
acid (pH 8.2) with 1 mM diethylenetriaminepentaacetic acid (DTPA). The homogenate 
was incubated on ice for 30 minutes to solubilize SOD from tissue followed by 
centrifugation at 16,000g for 30 minutes at 4˚C. The supernatant (2-4 ul) was mixed with 
200 ul assay buffer in 96-well micro plates in triplicate. The reaction was initiated by 
adding 25ul of 2 mM pyrogallol in 10 mM HCl, and the increase in absorbance at 405 nm 
was followed for 2 minutes by SPECTRA Fluor Plus plate reader (Tecan U.S. Inc., 
Durham, NC). SOD activity was assessed as the degree of inhibition of the pyrogallol 
autoxidantion rate. An inhibition of 50% by SOD standard was defined as 1 unit SOD. 
Sample protein concentration was measured by BCA method (Smith et al 1985). The 











Mice cardiac protein expression: The pattern of protein expression in mice heart 
by two-dimensional PAGE was consistent and identical for over 80% of all protein spots 
in 10 control and diabetic heart samples. Hundreds of proteins were visualized on the gel 
and over two hundred spots were detected by gel image analysis software. Figure 1 is a 
typical two-dimensional gel image showing the cardiac protein expression pattern in mice. 
Altered protein expression in diabetic heart: In our proteomic analysis comparing 
five control hearts to five OVE26 hearts, twenty-two proteins are found significantly 
altered in abundance, most of which have increased abundance in diabetic hearts.  The 
positions of these proteins are shown in Figure 1 by red arrowheads. Twenty of them 
gave signal strong enough to be identified by the mass spectrometry (Table 1).  
Among these twenty differentially expressed proteins, more than half of them are 
involved in energy metabolism, such as aconitase and isocitrate dehydrogenase for TCA 
cycle, enolase and aldolase for glycolysis, as well as 3-ketoacyl-CoA thiolase for fatty 
acid beta-oxidation. Some proteins are known to be induced by stress, such as prohibitin 
and crystallin.  There are also some proteins with unknown functions such as HSPC326. 
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Figure 1. Typical image of cardiac proteins. 
100ug protein extract from heart was run in two-dimension gel system and stained with 
SYPRO ruby fluorescent stain. Gel images were then photographed with a video camera 
and analyzed by HT analyzer. 22 proteins were significantly altered in OVE26 diabetic 
hearts compared to the control hearts, as spots indicated by arrows (n=5 each group, 




Table 1  
Proteins identified by mass spectrometry that altered their abundances in OVE26 hearts 
 
Spot Protein pI Mw OVE26/FVB P value
2 Aconitase 2, mitochondria 8.1 85 1.9 0.02
27 Dihydropyrimidinase related protein-2 (DRP-2)  6.0 63 1.5 0.01
43 Glucose regulated protein, 58 kDa;  6.0 57 1.6 0.01
65 ATP synthase, F1 complex, alpha 9.3 60 1.3 0.01
80 Enolase 3, beta muscle 6.7 47 0.5 0.01
86 Ornithine aminotransferase 6.2 49 1.6 0.01
88 NADP+-specific isocitrate dehydrogenase 9.2 51 1.8 0.02
92 Translation elongation factor EF-Tu precursor 6.8 50 0.8 0.05
103 GTP-specific succinyl-CoA synthetase beta subunit 5.9 44 1.5 0.01
105 3-ketoacyl-CoA thiolase, mitochondrial  8.4 42 2.3 0.01
108 Acyl coenzyme A thioester hydrolase, precursor 6.9 50 2.4 0.01
118 Aldolase 1, A isoform 8.8 40 1.8 0.02
123 Glutamate oxaloacetate transaminase 2 9.4 48 1.5 0.03
159 HSPC326 5.5 36 1.4 0.01
162 Enoyl coenzyme A hydratase 1 7.9 36 1.7 0.01
163 Prohibitin 5.6 30 1.3 0.03
179 (homolog to electron transfer flavoprotein beta subunit) 8.6 27 2.3 0.04
193 Proteosome (prosome, macropain) activator subunit 3 5.8 31 1.5 0.02
199 (homolog to ATP synthase D chain, mitochondrial 5.5 19 1.4 0.01
211 Crystallin, alpha 2; alpha B-crystallin 6.8 20 0.8 0.03
 
Spots correspond to the numbers on Figure 1. pI: isoelectric point. MW: molecular 
weight (KD). OVE26/FVB: the ratio of abundance in diabetic hearts divided by 
abundance in FVB hearts. P value: from t-test of OVE26 vs. FVB. 





up-regulated in diabetes. It has been reported that within a certain threshold, elevated 
ROS or reduced ATP production can induce a type of stress response to compensate 
impaired mitochondrial function by stimulating mitochondrial biosynthesis and/or 
increasing the expression of the genes required for energy metabolism (Fosslien 2001; 
Heddi et al 1999; Lee and Wei 2000). The fact that so many mitochondrial proteins are 
altered in abundance in diabetic heart also suggests that mitochondria might be a crucial 
target for ROS attack in diabetic cardiomyopathy. 
Mitochondrial morphology in OVE26 heart: In order to further investigate the 
possible mitochondrial damage in diabetic cardiomyopathy, transmission electron 
micrographs (TEM) of left ventricular myocardium were taken in FVB and OVE26 mice 
to look into the mitochondrial morphology at different ages. Figure 2 shows the cardiac 
ultrastructure at 2, 5 and 11 months of age in control (A,C,E) and diabetic (B,D,F) heart. 
The data clearly indicate the development of cardiomyopathy in our transgenic mice and 
the progressive damage to mitochondria over the time course. By the age of two months, 
OVE26 hearts began to show disarrangement of myofilaments and disruption of 
sarcomeres (Figure 2, panel A and B) while the mitochondria still kept normal structure 
and appearance. At 5 months, mitochondria abnormalities such as broken membranes and 
cristae as well as rarified matrices became evident (panel C and D). By eleven months of 
age, damages to both myofibrils and mitochondria were exacerbated, myelin figures 
become prominent and the overall cytoarchitecture was disrupted (panel E and F).  
A closer look at the cardiac mitochondria at 300-day-old diabetic mice (Figure 3) 
confirmed the damage we see in Figure 2. In some area, mitochondria are swollen or in 
irregular shape, some of them are even broken. Instead of the homogeneous dense matrix  
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Figure 2. Development of cardiomyopathy illustrated in representative TEMS of left 
ventricular myocardium in FVB (A,C,E) and OVE26 (B,D,F) mice at 2 months (A,B) 5 
months, (C,D) and 11 months (E,F). 
FVB mice showed normal myocardial ultraststructure at all ages (A,C,E) .  Myofibrils are 
comprised of regular and continuous sarcomeres that demarcated by Z-lines (arrowhead).  
Myofibrils are separated by straight rows of mitochondria (m) with homogeneously dense 
matrix.  In contrast, myocardium from matched OVE26 mice (B,D,F) showed severely  
disrupted myofibrils in all ages.  Mitochondria (m) damage was not detectable in two-
month-old heart (B), but by five months (D), mitochondria were loosely packed and 
highly disorganized. Focal areas showed mitochondria with broken membranes and 
cristae and their matrices appear mottled and regionally electron lucent.  This damage 
was even more evident at 11 months (F) where mitochondria were devoid of normal 
cristae structure and swollen with mottled matrix.  Numerous myelin figures suggested 



































Figure 3. Higher magnification (X28,000) transmission electron micrographs showing 
cardiac mitochondrial damage in 300-day-old OVE26 mice.  













 we see in the same age control heart, OVE26 mitochondria matrix was rarified and 
irregularly distributed.  
The mitochondrial damage we observed in diabetic heart EM photographs 
combined with the proteomics results strongly suggest that mitochondrial structure and 
probably function are impaired in diabetic cardiomyopathy, and this further leads to the 
compensatory induction of the proteins involved in energy metabolism. 
MnSOD protection: In an effort to prevent the abnormalities we saw in diabetic 
cardiomyopathy, especially the damage to mitochondria, we have developed transgenic 
lines that overexpress the major mitochondrial antioxidant enzyme, manganese 
superoxide dismutase (MnSOD), specifically in heart. The transgene shown in Figure 4 is 
constructed as described in methods. 
Characterization of these MnSOD transgenic lines is still in progress. Initial study 
done in 3 of the 5 transgenic lines shows the SOD activities in the heart were 30-60 fold 
higher compared to FVB mice (Figure 5). The increased SOD protein expression was 
also confirmed by two-dimension PAGE (Figure 6).  
We have just obtained data from the first OVE26-MnSOD mice.  While this data 
is very preliminary and from only one OVE26-MnSOD mouse it clearly suggests that 
MnSOD protected the heart from diabetes-induced damage to overall structure, 
cardiomyofibils, as well as mitochondria.   As shown in Figure 7, OVE26-MnSOD 






Figure 4. Construction of MySOD transgene. 
 α MHC promoter: murine alpha myosin heavy chain promoter; ADH: Alcohol 
dehydrogenase; Poly A: polyadenylation region of rat insulin II gene; MnSOD: complete 
































Figure 5. Enzyme assay shows increased SOD activity in 3 lines of MnSOD transgenic 
mice. 
Activities are shown as the fold increase in transgenic mice vs. control mice. Data were 
obtained from the mean of 2-5 mice in each of four groups. Assay will be repeated later 


























Figure 6. Comparison of 2-D gel images from control (A) and MnSOD (B) transgenic 
mice showing strong expression of SOD protein (dark circle). 
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Figure 7. Overexpression of MnSOD in heart prevents diabetic heart from morphology
damage. 
Representative transmission electron micrographs of left ventricle in FVB (A), OVE26








Cardiovascular disease is the major cause of morbidity and mortality from 
diabetes mellitus. In this paper, we studied the changes of protein expression in diabetic 
cardiomyopathy through our diabetic animal model – OVE26 transgenic mice. It is the 
first time for researchers to study systematically the protein expression in this disease. 
Proteomic analysis revealed over 20 proteins with altered abundance in a 4-month-old 
diabetic heart, most of which are involved in energy metabolism. We also noticed an 
unexpected high proportion of mitochondrial proteins that were altered. The fact that all 
of them are upregulated suggests that this compartment might be undergoing cellular 
damage in the diabetic state and a certain compensatory response is induced. Results 
from morphological study of cardiac mitochondria also showed progressive damage to its 
ultrastructure and appearance, further confirming our suspicions.  
Accumulating evidence suggests that reactive oxygen species (ROS) play a very 
important role in the development of diabetic cardiomyopathy, and mitochondria are the 
main source of ROS in the cell under most conditions. Excess ROS had been shown to be 
widely involved in diabetes and its many complications (Baynes 1991). Whether the 
superoxide produced by the mitochondria is upregulated in diabetes is still unclear. 
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However, aside from the well-known fact that mitochondria are the main intracellular 
source of oxidative stress, they are also the major target of ROS that are continually 
generated as the by-products from the respiratory chain under normal physiological 
conditions (Lee and Wei 2000). It has been suggested that a decline in mitochondrial 
function plays a critical role in aging and other degenerative diseases by producing 
excess ROS due to defects in the electron transport chain (Lee and Wei 2000; Wallace 
1999).  
Mitochondrial damage and dysfunction has been widely reported in diabetes and 
cardiomyopathy. Several laboratories including our own have found severe mitochondrial 
structural damage in diabetic heart electronmicrographs (Giacomelli and Wiener 1979). 
Evidence for mitochondrial dysfunction include depressed state 3 respiration and ATPase 
activity, decreased mitochondrial calcium uptake, as well as defective oxidative 
phosphorylation (OXPHOS) (Pierce and Dhalla 1985). Decreased pyruvate 
dehydrogenase activity and reduced activities of Complex I and Complex V have also 
been reported in the heart of STZ-induced diabetic animal models (Flarsheim et al 1996; 
Tomita et al 1996). Moreover, mitochondrial DNA (mtDNA) mutations have also been 
implicated in diabetes (Flarsheim, Grupp, and Matlib 1996; Graff et al 1999). Some 
characteristics of mitochondria such as a lack of protective histones for mtDNA and 
absence of an efficient repair system render mtDNA vulnerable to oxidative insult by 
ROS and prone to mutations (Lee and Wei 2000). Mutations in mtDNA can in turn 
deteriorate OXPHOS and reduce mitochondrial energy production (Esposito et al 1999). 
Because heart exclusively relies on mitochondrial ATP synthesis for contraction and ion 
transport, it makes sense that defective energy production would preferentially affect the 
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heart (Wallace 2000). In diabetic heart, long-term exposure to ROS might result in 
defective oxidative phosphorylation and bioenergy production, leading further to the 
development of cardiomyopathy. Our finding of upregulation of a significant number of 
mitochondrial proteins in diabetic cardiomyopathy is well in accordance with the above 
theory. 
Another possible explanation for the elevated percentage of mitochondrial 
proteins was that the mitochondrial mass was increased in 120-day-old diabetic mice. In 
morphological study, we did see swollen cardiac mitochondria with increased mass in the 
mice of 11 months age (Figure 2F). However, this increase was not so distinct in 5-
month-old diabetic heart (Figure 2D), and we consider it to be a minor factor that counted 
for the high proportion of mitochondrial proteins in 4-month-old diabetic hearts as we 
saw in proteomic results. 
 From the severe damage we saw in mitochondrial morphology, it is reasonable to 
postulate that mitochondrial function might be affected by ROS attack as well. Our next 
study is to investigate mitochondrial integrity and activity under the diabetic state. Initial 
data from Shirong Zheng, a postdoctoral fellow in our laboratory, shows that in OVE26 
cardiac mitochondria, even though P/O remains the same as control, RCR is significantly 
decreased (data not shown), suggesting impaired control of mitochondrial metabolism 
and possibly reduced rate of ATP synthesis. We will also measure the activities of four 
complexes in mitochondrial electron transport chain to study the effect of oxidative stress 
on mitochondrial functions.  
 In support of our hypothesis that ROS induced mitochondrial damage in diabetic 
cardiomyopathy, initial results from MnSOD transgenic mice has shown that 
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overexpression of MnSOD in diabetic heart successfully blocked diabetes-induced 
damage in heart morphology. Since MnSOD only protects against ROS, this result 
suggests that ROS causes the morphology damage in diabetic hearts. We are planning to 
further study the protective effect of MnSOD in diabetic heart from protein expression, 
ROS production, mitochondrial function, as well as cardiomyocyte contractility. These 
studies will be a part of our continued efforts to find an effective antioxidant regimen for 
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